A GENE THERAPY FOR BLINDNESS HAS BEEN APPROVED BY THE FDA, BUT AFFORDABILITY REMAINS PROBLEMATIC

Winchester, VA – Luxturna is a new gene therapy which was developed to treat progessive blindness and received FDA approval last year. The condition it treats is an inherited genetic disease resulting from mutations in the RPE65 gene. Only a few thousand people in the United States are affected by it. The gene mutation disrupts the cells located near the retina, causing the victim to gradually lose their vision. Luxturna therapy involves the injection of a modified adeno-associated cold virus into the eye to deliver the correct genes to the retina.

CRUSADE Channel News is a service of the Veritas Radio Network and is supported by listeners and readers just like you! Please consider becoming a Founder’s Pass Member by clicking here; making a purchase in our Founder’s Tradin Post Store by clicking here; or a donation by clicking here.